Oncology Speed Read Video overview 

The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Prof. Chiara Cremolini

Prof. Chiara Cremolini
Publication Date

Jul 2025

info Summary and next episodes download Downloadable resources

Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H metastatic colorectal cancer (mCRC), with a particular focus on the following two studies: 

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC 
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC 

Watch the short video for a summary of Professor Cremolini’s perspectives.  Download the slide deck for more details on the data. 

  • Understand clinical trial data and real-world evidence of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC and relevant patient subgroups 
  • Recognise the appropriate sequencing of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC across the patient journey to ensure optimal outcomes 

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Prof. Chiara Cremolini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants for research projects:

Bayer, Merck, Nordic Pharma, Pierre Fabre, Roche, Servier, Takeda, Tempus, 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H metastatic colorectal cancer (mCRC), with a particular focus on the following two studies: 

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC 
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC 

Watch the short video for a summary of Professor Cremolini’s perspectives.  Download the slide deck for more details on the data. 

  • Understand clinical trial data and real-world evidence of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC and relevant patient subgroups 
  • Recognise the appropriate sequencing of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC across the patient journey to ensure optimal outcomes 

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Prof. Chiara Cremolini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants for research projects:

Bayer, Merck, Nordic Pharma, Pierre Fabre, Roche, Servier, Takeda, Tempus, 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock
Programme summary
Watch the video now
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
GI CONNECT PRECISION ONCOLOGY CONNECT GI NURSES CONNECT
Educational programme supported by an Independent Educational Grant from Amgen.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 10 MIN
  • calendar Jun 2025
  • Non-accredited Independent Medical Education
GI CONNECT GI NURSES CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC)

Expert opinion on the latest practice-changing data

Experts
Prof. Dominik Modest, Dr Sara Lonardi
  • clock 5 MIN
  • calendar Jun 2025
  • Non-accredited Independent Medical Education
GI CONNECT GI NURSES CONNECT PRECISION ONCOLOGY CONNECT
This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
podcast Video podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network PanCAN
National Pancreas Foundation
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025
  • Non-accredited Independent Medical Education
GI CONNECT GI NURSES CONNECT
Educational programme supported by an Independent Educational Grant from Ipsen USA
conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
MET crusaders ESDO Global Liver Institute
DiCE
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education
COR2ED GI NURSES CONNECT PRECISION ONCOLOGY CONNECT GU NURSES CONNECT GI CONNECT
Explore all programmes